We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.46 | -1.50% | 95.81 | 97.83 | 97.11 | 97.63 | 1,180,796 | 00:00:00 |
From May 2019 to May 2024
By Marc Bisbal Arias
Novartis AG (NOVN.EB) said Tuesday that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute to develop cancer therapy systems.
The Swiss pharmaceutical company has reached a collaboration and licensing agreement to develop biomaterial systems for its portfolio of immuno-oncology therapies.
The aim of the licensed systems is to overcome barriers that have hampered traditional cancer vaccines, it said.
Novartis will collaborate with the Wyss Institute to advance development of biomaterial systems that researchers have engineered to provide sustained delivery of immunotherapies and target specific types of cancer.
The technologies licensed under the agreement are owned or co-owned by Harvard University, Dana-Farber and the University of Michigan, it said.
Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com
(END) Dow Jones Newswires
March 20, 2018 03:02 ET (07:02 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
